— Financial reporting — Consolidated income statement
Consolidated income statement
January 1 – June 30
millions of CHF |
|
Notes |
|
2023 |
|
2022 1) |
|
Revenue |
|
3 |
|
248.1 |
|
250.6 |
|
Cost of goods sold |
|
|
|
–166.1 |
|
–151.4 |
|
Gross profit |
|
|
|
82.0 |
|
99.2 |
|
Selling and administrative expenses |
|
|
|
–57.2 |
|
–52.5 |
|
Research and development expenses |
|
|
|
–12.9 |
|
–12.3 |
|
Other operating income/(expenses), net |
|
5 |
|
2.5 |
|
–17.6 |
|
Operating income |
|
|
|
14.5 |
|
16.9 |
|
Interest income |
|
6 |
|
0.3 |
|
0.0 |
|
Interest expenses |
|
6 |
|
–4.2 |
|
–3.0 |
|
Other financial income/(expenses), net |
|
6 |
|
–1.6 |
|
–0.2 |
|
Income before tax expenses |
|
|
|
9.0 |
|
13.7 |
|
Income tax expenses |
|
7 |
|
–1.7 |
|
–4.5 |
|
Total net income |
|
|
|
7.3 |
|
9.2 |
|
|
|
|
|
|
|
|
|
Earnings per share (in CHF) |
|
|
|
|
|
|
|
Basic earnings per share |
|
|
|
0.18 |
|
0.23 |
|
Diluted earnings per share |
|
|
|
0.18 |
|
0.22 |
|
1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.